| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTHrP |
| Uniprot No | P12272 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-175aa |
| 氨基酸序列 | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR |
| 预测分子量 | 19.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTHrP(甲状旁腺激素相关蛋白)重组蛋白的3篇代表性文献及其摘要内容：
1. **《A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression》**
- **作者**：Suva LJ, et al.
- **摘要**：该研究首次克隆并表达了PTHrP基因，揭示了其在恶性肿瘤相关高钙血症中的作用机制，为后续研究其结构与功能奠定了基础。
2. **《The hypercalcemia of cancer: pathogenesis and clinical management》**
- **作者**：McCauley LK, Martin TJ
- **摘要**：综述了PTHrP在癌症高钙血症中的核心作用，重点讨论了重组PTHrP在体外实验中对骨代谢和肿瘤微环境的影响。
3. **《Parathyroid hormone-related protein (PTHrP): a nucleocytoplasmic shuttling protein with distinct paracrine and intracrine roles》**
- **作者**：Wysolmerski JJ, et al.
- **摘要**：探讨了重组PTHrP的双重功能：作为分泌型蛋白调节钙稳态，以及通过核定位信号影响细胞增殖和分化的非经典作用。
4. **《PTH and PTHrP in skeletal development and disease》**
- **作者**：Kronenberg HM, Lanske B
- **摘要**：分析了重组PTHrP在骨骼发育和疾病模型中的应用，强调其在调节软骨细胞分化和治疗骨质疏松症中的潜在价值。
以上文献涵盖了PTHrP重组蛋白的分子机制、病理作用及治疗研究，可根据具体研究方向进一步查阅。
**Background of PTHrP Recombinant Protein**
Parathyroid hormone-related protein (PTHrP) is a multifunctional polypeptide initially identified for its role in humoral hypercalcemia of malignancy (HHM), where tumor-secreted PTHrP mimics parathyroid hormone (PTH) to disrupt calcium homeostasis. Structurally, PTHrP shares limited N-terminal homology with PTH, enabling both to bind the PTH type 1 receptor (PTH1R), activating pathways like cAMP/PKA and PLC/PKC. However, unlike PTH, which primarily regulates calcium and phosphate metabolism, PTHrP exerts broader autocrine, paracrine, and intracrine effects across tissues, influencing cell proliferation, differentiation, apoptosis, and embryonic development.
Recombinant PTHrP is produced via genetic engineering in bacterial (e.g., *E. coli*) or mammalian expression systems, ensuring high purity and activity for research and therapeutic applications. Its production bypasses challenges associated with isolating native PTHrP, which is unstable and low in abundance. Recombinant forms allow precise study of PTHrP’s roles in skeletal biology, cancer progression, cardiovascular function, and mammary gland development. For instance, in bone, PTHrP regulates chondrocyte differentiation during endochondral ossification, while in breast tissue, it supports lactation.
Therapeutically, recombinant PTHrP analogs are explored for bone disorders, though clinical use remains limited. Research tools like recombinant PTHrP are vital for dissecting signaling mechanisms, developing receptor antagonists, or testing targeted therapies for cancers driven by PTHrP overexpression. Overall, recombinant PTHrP serves as a cornerstone for understanding this protein’s dual role in physiology and disease.
×
